News & Publications for:

Jeffrey Milbrandt

Jeffrey Milbrandt‘s Faculty Page

Startup company founded by Washington University scientists acquired by Eli Lilly

Posted on October 21, 2020

Drugmaker purchases Disarm Therapeutics to develop treatments for neurodegenerative diseases Read More

Posted in: Axon Injury & Repair, News Faculty: ,

SARM1 acts downstream of neuroinflammatory and necroptotic signaling to induce axon degeneration

Posted on July 14, 2020

Kwang Woo Ko, Jeffrey Milbrandt, Aaron DiAntonio. The Journal of Cell Biology, Volume 219, Issue 8, 3 August 2020 Read More

Posted in: Axon Injury & Repair, Publications Faculty: ,

Peripheral nerve resident macrophages share tissue-specific programming and features of activated microglia

Posted on May 29, 2020

Peter L. Wang, Aldrin K. Y. Yim, Ki-Wook Kim, Denis Avey, Rafael S. Czepielewski, Marco Colonna, Jeffrey Milbrandt & Gwendalyn J. Randolph. Nature Communications, Volume 11, Issue 1, 1 December 2020, Article number 2552 Read More

Posted in: Axon Injury & Repair, HPAN, Neurogenetics & Transcriptomics, Publications Faculty: ,

Cell-autonomous expression of the acid hydrolase galactocerebrosidase

Posted on April 28, 2020

Christina R. Mikulka, Joshua T. Dearborn, Bruno A. Benitez, Amy Strickland, Lin Liu, Jeffrey Milbrandt, and Mark S. Sands. Proceedings of the National Academy of Sciences of the United States of America, Volume 117, Issue 16, 21 April 2020, Pages 9032-9041 Read More

Posted in: Axon Injury & Repair, Lysosome, Publications Faculty: ,

cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons

Posted on April 21, 2020

Yo Sasaki,Thomas M. Engber, Robert O. Hughes, Matthew D. Figley, Tong Wu, Todd Bosanac, Rajesh Devraj, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio. Experimental Neurology, Volume 329, July 2020, Article number 113252 Read More

Posted in: Axon Injury & Repair, Publications Faculty: ,